Document Detail


Relationships between cell-free DNA and serum analytes in the first and second trimesters of pregnancy.
MedLine Citation:
PMID:  20733451     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To assess the relationship between first- and second-trimester cell-free DNA levels and maternal serum screening markers.
METHODS: First- and second-trimester residual maternal serum samples from 50 women were obtained. First-trimester (pregnancy-associated plasma protein A and beta-hCG) and second-trimester serum analytes (beta-hCG, alpha-fetoprotein, unconjugated estriol, and inhibin A) had been measured at the time of sample receipt. All fetuses were male as confirmed by birth records. Cell-free DNA was extracted and measured by real-time quantitative polymerase chain reaction amplification using glyceraldehyde phosphate dehydrogenase and DYS1 as markers of total DNA and fetal DNA, respectively. Determination of linear associations between first- and second-trimester serum markers and cell-free DNA levels using Pearson correlations was performed.
RESULTS: Statistically significant correlations between first-trimester pregnancy-associated plasma protein A multiples of the median and both total (r=0.36, P=.016) and fetal (r=0.41, P=.006) DNA in the first trimester were observed. There were no significant correlations between first-trimester serum human chorionic gonadotropin or any second-trimester serum marker with DNA levels.
CONCLUSION: Correlation between serum pregnancy-associated plasma protein A and first-trimester circulating cell-free fetal and total DNA levels is a novel finding. Pregnancy-associated plasma protein A is a glycoprotein of placental origin, and its correlation to cell-free fetal DNA in maternal serum suggests a common tissue origin through apoptosis of placental cells. However, because pregnancy-associated plasma protein A and cell-free DNA were only marginally correlated and cell-free DNA can be reliably detected in the first trimester, the addition of cell-free DNA to serum screening strategies may be helpful in predicting adverse pregnancy outcome.
LEVEL OF EVIDENCE: II.
Authors:
Neeta L Vora; Kirby L Johnson; Geralyn Lambert-Messerlian; Hocine Tighiouart; Inga Peter; Adam C Urato; Diana W Bianchi
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  116     ISSN:  1873-233X     ISO Abbreviation:  Obstet Gynecol     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-24     Completed Date:  2010-09-28     Revised Date:  2011-10-14    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  673-8     Citation Subset:  AIM; IM    
Affiliation:
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, Massachusetts, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Biological Markers / blood*
DNA / blood*
Female
Humans
Mass Screening
Pregnancy / blood*
Pregnancy Complications / diagnosis
Pregnancy Trimester, First / blood*
Pregnancy Trimester, Second / blood*
Pregnancy-Associated Plasma Protein-A / metabolism
Grant Support
ID/Acronym/Agency:
HD42053-07/HD/NICHD NIH HHS; R01 HD042053-07/HD/NICHD NIH HHS; R01 HD042053-09/HD/NICHD NIH HHS; T32 HD049341/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Biological Markers; 9007-49-2/DNA; EC 3.4.24.-/Pregnancy-Associated Plasma Protein-A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Recurrent preeclampsia: the effect of weight change between pregnancies.
Next Document:  Effects of deployment on depression screening scores in pregnancy at an army military treatment faci...